Cargando…
P1276: DOSE RESPONSE PROFILE OF IGM-2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON-HODGKIN’S LYMPHOMA
Autores principales: | Leabman, M. K., Hernandez, G., Ng, C. M., Tang, J., Pandya, D., Hart, K. C., Li, K., Hinton, P. R., So, J., Qazi, I., Cheah, C. Y., Kim, W. S., Budde, E., Gopal, A. K., Manley, T., Takimoto, C. H., Sinclair, A. M., Carroll, S. F., Keyt, B. A., Kotturi, M. F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429641/ http://dx.doi.org/10.1097/01.HS9.0000847968.95263.25 |
Ejemplares similares
-
P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
por: Hart, Kevin C., et al.
Publicado: (2023) -
Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
por: Wang, Beatrice T., et al.
Publicado: (2021) -
Structure, Function, and Therapeutic Use of IgM Antibodies
por: Keyt, Bruce A., et al.
Publicado: (2020) -
Adjunctive IgM-enriched immunoglobulin therapy with a personalised dose based on serum IgM-titres versus standard dose in the treatment of septic shock: a randomised controlled trial (IgM-fat trial)
por: Biagioni, Emanuela, et al.
Publicado: (2021) -
DETECTION OF MEASLES IgM
por: Lievens, Alan W, et al.
Publicado: (1984)